Eli Lilly's chief executive told CNBC that roughly one-third of patients new to GLP-1 therapy are choosing Foundayo, the company's oral formulation of tirzepatide. The disclosure reveals strong early traction for the pill-based treatment as Lilly accelerates manufacturing capacity to meet surging demand.
Foundayo represents a critical strategic pivot for Lilly in the hypercompetitive GLP-1 market. The oral tablet competes directly against Novo Nordisk's Ozempic and Wegovy injections, which have dominated the weight-loss and diabetes sectors for over a year. The shift from injection to pill form removes a major patient barrier. Injection-averse consumers now have a viable Lilly alternative that delivers tirzepatide through daily oral dosing rather than weekly shots.
One-third market capture among new GLP-1 initiates signals that patient preference favors convenience. Lilly's production ramp matters because supply constraints plagued first-generation GLP-1 players throughout 2023 and into 2024. Novo Nordisk faced chronic shortages of Ozempic and Wegovy that extended waiting lists and frustrated physicians. Lilly appears determined not to repeat that misstep. By front-loading manufacturing investment before demand peaks, the company positions itself to capture share from competitors unable to fulfill orders.
The broader market context intensifies competition. Novo Nordisk maintains the installed user base and brand recognition. Pfizer launched danuglipron as an oral GLP-1 in late 2023 but faced tolerability issues that limited uptake. Viking Therapeutics is advancing VK2735, a next-generation dual GLP-1 and GIP receptor agonist in Phase 2 trials. Amgen entered the race with MariTide, a monthly injection requiring only two doses per year. Each player targets the same trillion-dollar obesity and diabetes opportunity.
Foundayo's one-third conversion rate of new patients matters on several levels. First, it validates demand for oral formulations in a market accustomed to injections. Second, it demonstrates that Lilly's manufacturing and supply chain can handle real-world volume. Third, it signals that the company will capture meaningful revenue from the GLP-1 expansion even as competitors proliferate.
Lilly's stock performance has reflected investor confidence in the tirzepatide franchise. The company trades on expectations that Mounjaro (the diabetes indication) and Zepbound (the weight-loss indication) will generate tens of billions in annual revenue by 2030. Foundayo amplifies that thesis by expanding the addressable patient pool to those uncomfortable with needles.
Wall Street analysts model the GLP-1 market reaching 100 million users by 2035. Lilly's stated goal to capture 30 to 40 percent of that market hinges on supply reliability and patient choice. The CEO's disclosure that one-third of new GLP-1 patients choose Foundayo suggests the company is on track. However, execution risk remains. Production delays, manufacturing quality issues, or regulatory setbacks could derail momentum.
Investors watching Lilly should monitor quarterly tirzepatide prescriptions, revenue guidance for both Mounjaro and Zepbound, and Foundayo uptake metrics in coming earnings reports. The company's ability to scale manufacturing without compromising quality will determine whether it converts early Foundayo adoption into sustained market share gains.